Tau passive immunization inhibits not only tau but also Aβ pathology by unknown
RESEARCH Open Access
Tau passive immunization inhibits not only
tau but also Aβ pathology
Chun-ling Dai, Yunn Chyn Tung, Fei Liu, Cheng-Xin Gong and Khalid Iqbal*
Abstract
Background: Accumulation of hyperphosphorylated tau protein is a histopathological hallmark of Alzheimer’s
disease (AD) and related tauopathies. Currently, there is no effective treatment available for these progressive
neurodegenerative diseases. In recent years, tau immunotherapy has shown great potential in animal models. We
report the effect of immunization with tau antibodies 43D against tau 6–18 and 77E9 against tau 184–195 on tau
and amyloid-β (Aβ) pathologies and cognition in triple-transgenic (3×Tg)-AD mice at mild to moderate stages of
the disease.
Methods: We immunized 12-month-old female 3×Tg-AD mice with two to six or seven intravenous weekly doses
of 15 μg of mouse monoclonal antibody 43D, 77E9, a combination of one-half dose each of 43D and 77E9, or as
control of mouse immunoglobulin G (IgG). Age-matched wild-type mice treated with mouse IgG or a mixture of
43D and 77E9 were also used as controls. The effect of immunization with tau antibodies on tau and Aβ
pathologies was assessed by Western blot and immunofluorescence analysis, and the effect on cognition was
analyzed by using Morris water maze, one-trial novel object recognition, and novel object location tasks.
Results: We found that two doses of 43D and 77E9 reduced total tau but had no significant impact on
hyperphosphorylation of tau. However, six doses of 43D reduced levels of both total tau and tau
hyperphosphorylated at Ser262/356 and Ser396/404 sites in the hippocampus. Importantly, both 43D and 77E9
antibodies rescued spatial memory and short-term memory impairments in 3×Tg-AD mice. The beneficial effect of
43D and 77E9 antibodies on cognitive performance was sustained up to 3 months after the last dose. Six doses of
immunization with 43D also decreased amyloid precursor protein (APP) level in CA1 and amyloid plaques in
subiculum, and showed a trend toward reducing Aβ40 and Aβ42 in the forebrain. Immunization with 43D
increased levels of complement components C1 and C9 and resulted in activation of microglia, especially
surrounding Aβ plaques.
Conclusions: These findings suggest the potential of passive immunization targeting proximal N-terminal domain
tau 6–18 as a disease-modifying approach to AD and related tauopathies.
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Background
Alzheimer’s disease (AD), which is characterized by
progressive loss of memory and other cognitive functions,
is the most common cause of dementia. AD is the sixth
leading cause of death in the United States [1]. The two
major histopathological hallmarks in brains of patients with
AD are extracellular senile plaques consisting of amyloid-β
(Aβ) peptides [2] and intracellular neurofibrillary tangles
(NFTs) composed of abnormally hyperphosphorylated tau
protein [3]. The tau pathology made up of the
hyperphosphorylated tau is also a hallmark of several
neurodegenerative disorders known as tauopathies, includ-
ing frontotemporal dementia, corticobasal degeneration,
progressive supranuclear palsy, Pick disease, parkinsonism-
dementia complex of Guam, and chronic traumatic
encephalopathy. Currently, there are no effective treatments
available for AD and related tauopathies. Based on an Aβ
cascade hypothesis [4], most therapeutic approaches
including Aβ immunotherapy for AD are focused mainly
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on reducing Aβ plaques in the brain [5, 6]. To date, none of
the treatments available for AD slow or stop neurodegener-
ation. Clinical trials with Aβ therapies, including immuno-
therapy, have thus far failed to show any reduction in
neurofibrillary pathology or improvement in cognitive per-
formance of patients with AD [5–10].
Multivariate analyses indicate that the density of NFTs,
neuron number loss, and synapse loss, but not amyloid
load, strongly correlates with cognitive impairment in
patients with AD [11–14]. Thus, targeting tau pathology
could be clinically more efficacious than Aβ-directed
clearance therapy for patients with AD. Indeed, active
and passive immunotherapies targeting pathological tau
have been tested in several transgenic mouse models of
AD using different phospho-tau peptides and antibodies,
and they have shown great potential [15]. Active
immunization with tau phosphopeptides reduces tau
pathology [16–22] and rescues or slows cognitive decline
in rodents [16, 19, 21, 22]. Passive immunotherapy using
antibodies against tau has also been shown to slow dis-
ease progression [19, 23–28].
Based on the success of tau immunization in trans-
genic mouse models of overexpression of disease-
causing mutated taus, tau immunotherapy is becoming a
rapidly growing area of drug development in clinical tri-
als. A phase I study of the first tau immunotherapy tar-
geting active immunization against tau 294–305 in
patients with AD has been completed, and recruitment
of patients for a phase II human clinical trial is ongoing
(ClinicalTrials.gov identifier: NCT02579252; AXON
Neuroscience SE, Bratislava, Slovak Republic). ACI-35 is
a liposome-based vaccine targeting tau 393–408 that has
been tested in a completed phase I study and is now be-
ing evaluated in a phase Ib trial of patients with mild to
moderate cases of AD [29]. More recently, additional
clinical trials targeting passive immunization were initi-
ated, which include one against N-terminal fragment of
tau (tau 17–28; BMS-986168/IPN007) by Bristol-Meyers
Squibb (ClinicalTrials.gov identifier: NCT02294851;
BMS-986168) and another against tau pSer422 (tau
416–430; RO6926496) by Hoffman-La Roche (Clinical-
Trials.gov identifier: NCT02281786). In addition, a phase
I study with C2N-8E12 antibody in patients with pro-
gressive supranuclear palsy (ClinicalTrials.gov identifier:
NCT02494024; C2N Diagnostics) is ongoing.
Previously, we discovered that abnormally hyperpho-
sphorylated tau from patients with AD, instead of inter-
acting with tubulin and promoting its assembly into
microtubules, sequesters normal tau, forming oligomers
and consequently filaments that can be sedimented at
100,000–200,000 g [30–32]. This finding, which formed
the basis of tau spread studies [33–36], led us to test the
removal of pathological tau by passive immunization
using antibodies to N-terminal domains of tau.
Tau pathology is well documented to propagate in a
predictable pattern [37, 38]. The abnormally hyperpho-
sphorylated/oligomeric tau released in the extracellular
space from the affected neurons is suspected to serve as
the seed for the spread of tau pathology by the ingesting
cells [33, 36, 39, 40]. Tau immunotherapy may clear
extracellular tau that is involved in the spreading of tau
pathology [23, 41].
In a previous study, we discovered that passive
immunization with tau antibody to the N-terminal do-
main of tau not only reduced tau pathology but also
showed a trend toward ameliorating Aβ pathology in
triple-transgenic (3×Tg)-AD mice at moderate to severe
stages of the disease [28]. In the present study, we ad-
ministrated tau antibodies by intravenous injection into
3×Tg-AD mice at a mild stage of the pathology
(12 months old) once weekly for up to 6 weeks; 3×Tg-
AD mice start developing Aβ plaques at approximately
9 months and tau pathology starts at approximately
12 months [42–44]. We found that passive
immunization with monoclonal antibody 43D against
tau 6–18 could reduce not only tau but also Aβ path-
ology in 3×Tg-AD mice and that the N-terminal prox-
imal domain of tau was a more effective target for




Primary antibodies used in this study are listed in
Table 1. Peroxidase-conjugated antimouse and antirabbit
immunoglobulin G (IgG) were obtained from Jackson
ImmunoResearch Laboratories (West Grove, PA, USA).
We used an enhanced chemiluminescence kit from
Pierce Biotechnology (Rockford, IL, USA). Human Aβ1–
40 and human Aβ1–42 enzyme-linked immunosorbent
assay (ELISA) kits were obtained from Invitrogen (Carls-
bad, CA, USA). Modified Dulbecco’s PBS buffer was ob-
tained from Thermo Fisher Scientific (Waltham, MA,
USA). Other chemicals were purchased from Sigma-
Aldrich (St. Louis, MO, USA).
Immunization of animals
Mouse monoclonal tau antibodies 43D against tau 6–18
and 77E9 against tau 184–195 were generated at our in-
stitute. Both 43D and 77E9 were IgG1 kappa light chain.
Briefly, recombinant human tau 441 purified from
Escherichia coli was used as the immunogen. Tau was
emulsified in the presence of complete Freund’s adjuvant
(1:1 vol/vol; Difco Laboratories, Detroit, MI, USA) with
the minichanger of an Omni Mixer (Omni International,
Kennesaw, GA, USA) at 4 °C. BALB/cJ mice (7 weeks
old; The Jackson Laboratory, Bar Harbor, ME, USA)
were inoculated intradermally and subcutaneously with
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tau as previously described [45]. The animals were bled
retro-orbitally and monitored for antibody response by
the ELISA procedure.
Production of hybridomas
Spleen cells were fused to the NS0 myeloma cell line. Initial
screening of hybridoma supernatants from 96-well plates
was performed by ELISA. Each selected hybridoma was
cloned three times by limiting dilution and used to produce
ascites in 2,6,10,14-tetrametylpentadecane (Pristane; Sigma-
Aldrich)-primed mice. An Ig subtype identification kit
(Boehringer Mannheim Biochemical, Indianapolis, IN,
USA) was used for isotyping the antibody.
Epitope mapping
Epitope mapping of each tau antibody was carried out
using 12-mer overlapping synthetic tau peptide manu-
factured by Pepscan (Lelystad, The Netherlands).
Mice
The homozygous 3×Tg-AD mice harboring human
APPSWE and tauP301L transgenes with knock-in PS1M146V
under the control of the mouse Thy1.2 promoter,
created in the laboratory of Dr. Frank LaFerla [42], were
obtained from The Jackson Laboratory (https://
www.jax.org/strain/004807). Homozygous male and fe-
male 3×Tg-AD mice on the mixed C7BL/6;129X1/
SvJ;129S1/Sv genetic background were bred in the
animal colony of New York State Institute for Basic
Research in Developmental Disabilities (Staten Island,
NY, USA). Mice had access to food and water ad libitum
and were housed (four or five animals per cage) in
pathogen-free facilities with 12-h light/12-h dark cycles.
The female 3×Tg-AD mice develop amyloid plaques
starting at about 9 months of age and NFTs starting
about 12 months of age, respectively, and the patholo-
gies are predominantly restricted to the hippocampus,
amygdala, and cerebral cortex [42–44].
B6129SF2/J strain mice, used as wild-type (WT)
controls in the present study, were the offspring of a
cross between C57BL/6J females (B6) and 129S1/SvImJ
males (129S); they are commonly used as controls for
genetically engineered strains generated with 129-
derived embryonic stem cells and maintained on a
mixed B6;129 background (https://www.jax.org/strain/
101045).
To avoid the effect of the variations among the mice
on the results, at the beginning of the present study, all
mice used were first grouped according to their body
weight and age, and the mice from the same litter were
evenly assigned to different groups. Then the grouped
mice were randomized into (1) WT mice treated with
IgG, (2) WT mice treated with tau antibodies 43D +
77E9, (3) 3×Tg-AD mice treated with IgG, (4) 3×Tg-AD
mice treated with 43D, (5) 3×Tg-AD mice treated with
77E9, and (6) 3×Tg-AD mice treated with 43D + 77E9.
Immunization with tau antibodies
To investigate the dose-dependent effect of passive
immunization with N-terminal tau antibodies on reduc-
tion of tau pathology, we immunized the 3×Tg-AD mice
(four or five mice per group) intravenously with 15 μg of
Table 1 Primary antibodies used in this study
Antibody Type Specificity Phosphorylation sites Source/reference
43Da Monoclonal Tau Covance (Princeton, NJ, USA)
77E9a Monoclonal Tau Covance
R134d Polyclonal Tau [77]
GAPDH Polyclonal GAPDH Santa Cruz Biotechnology (Dallas, TX, USA)
pS199 Polyclonal p-tau Ser199 Invitrogen (Carlsbad, CA, USA)
AT8 Monoclonal p-tau Ser202/Thr205 Thermo Fisher Scientific (Waltham, MA, USA)
pT205 Polyclonal p-tau Thr205 Invitrogen
12E8 Monoclonal p-tau Ser262/356 Dr. D. Schenk, Elan Pharmaceuticals (South San Francisco, CA, USA)
PHF1 Monoclonal p-tau Ser396/404 Dr. P. Davies, Albert Einstein College of Medicine (Bronx, NY, USA)
APP Polyclonal APP Generated in our institute
4G8 Monoclonal APP/Aβ BioLegend (San Diego, CA, USA)
Iba1 Polyclonal Iba1 Abcam (Cambridge, MA, USA)
Iba1 Polyclonal Iba1 for IHC Wako Chemicals (Richmond, VA, USA)
C1q Monoclonal C1q Thermo Fisher Scientific
C9 Polyclonal C9 Thermo Fisher Scientific
Abbreviations: APP Amyloid precursor protein, Aβ Amyloid-β, GAPDH Glyceraldehyde 3-phosphate dehydrogenase, IHC Immunohistochemistry, PHF1 Paired helical
filament 1, pS199 Phospho-tau (Ser199), pT205 Phospho-tau (Thr205), p-tau Phosphorylated tau
aImmunoglobulin G1 kappa light chain
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43D, 77E9, and as controls with mouse IgG in 200 μl of
saline once per week for 2 or 6 weeks. Animals were
killed 1 day after their last immunization.
To investigate the effect of 43D and 77E9 on cogni-
tion, 12-month-old female mice were used, and behav-
ioral tests were carried out 1 day after the sixth
immunization. After behavioral tests, animals received
one more dose on day 66, and five or six mice per group
were killed on day 72. The remaining mice were housed
for another 4 months. A one-trial novel object location
test was carried out before these mice were killed
(Fig. 1).
After removal of brain, one-half of the brain was fixed
in 4% paraformaldehyde for histological and immunohis-
tological studies, and the other half was dissected into
forebrain including hippocampus and stored at −80 °C
for biochemical analysis.
General examination
A general examination of all the mice was conducted in
the home cages throughout the whole study. Any gross
abnormalities in overall health, home cage nesting,
sleeping, feeding, grooming, and condition of the fur of
animals were noted. Body weight was measured once
per week during the study period.
Morris water maze task
The Morris water maze task was used to evaluate spatial
learning and memory of the mice [46, 47]. A total of 74
mice were subjected to the Morris water maze task from
1 day after the sixth immunization. The test was per-
formed in a circular white pool (with a diameter of
180 cm and a height of 60 cm) filled with nontoxic white
dye-tinted water and maintained at room temperature
(20 ± 1 °C). The maze was designed with two virtual
principal axes, with each line bisecting the maze perpen-
dicular to the other one to divide the maze into four
equal quadrants. The end of each line demarcates four
cardinal points: north, south, east, and west. A platform
was positioned in the middle of one of the quadrants
submerged 1 cm below the water surface. Each mouse
performed two trials on day 1 and 2, three trials on day
3, four trials on days 4 and 5 for 5 consecutive days from
semirandom start positions [48] to find the hidden plat-
form. Each trial was terminated as soon as the mouse
climbed onto the hidden platform. If a mouse failed to
find the platform within 90 seconds, it was gently guided
to the platform. At the end of each trial, the mouse was
left on the platform for 20 seconds, then removed, dried,
and returned to its home cage. A 90-second probe test
without platform was performed 24 h after the last trial.
Escape latency (seconds) in initial training as well as
latency to first entrance into target (platform location
area), target crossings, swim speed (centimeters per
second), and time spent in each quadrant (seconds) in
the probe test were recorded through an automated
tracking system (Panlab SMART video tracking system
version 2.0.14; Harvard Apparatus, Holliston, MA,
USA).
One-trial novel object recognition task
The one-trial object recognition test is based on the
innate tendency of rodents to explore novel objects over
familiar ones and is believed to measure episodic mem-
ory. The experimental procedure was performed as
described previously [49, 50]. Testing consisted of three
different phases: a habituation phase, a sample phase,
and a test phase. Following initial exposure, four
additional 10-minute daily habituation sessions were
performed for mice to become familiar with the appar-
atus (50 × 50 × 40 cm) and the surrounding environment.
On the fifth day, every mouse was first subjected to the
sample phase, in which two identical objects were placed
in a symmetrical position from the center of the arena
and the mouse was allowed to freely explore the objects
for 8 minutes. After a 20-minute delay during which the
Fig. 1 Study design. 3×Tg-AD mice were subjected to Morris water maze and one-trial novel object recognition tasks after immunization with six
doses of mouse IgG (control), 43D, 77E9, and combination (50% each) of 43D and 77E9 antibodies. On day 66, the mice were administrated one
more dose; five or six mice per group were killed on day 72; and the remaining animals were killed on day 180. The novel object location test
was carried out from day 165 to day 167. WT mice immunized with mouse IgG or a combination of 43D and 77E9 were used as controls. AD
Alzheimer’s disease, IgG Immunoglobulin G, MWM Morris water maze, NOR Novel object recognition, 3×Tg Triple-transgenic, WT Wild type
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mouse was returned to its home cage, the animal was
reintroduced into the arena to perform the test phase.
The mouse was then exposed to two objects for another
5 minutes: a familiar object (previously presented during
the sample phase) and a novel object, placed at the same
location as during the sample phase. Data collection was
performed using a video tracking system (ANY-maze
version 4.5 software; Stoelting Co., Wood Dale, IL,
USA). The object discrimination index was evaluated by
the index [(time spent exploring the new object)/(time
spent exploring both old and new objects) × 100%] dur-
ing the test phase.
Novel object location task
The object location memory task has been used to
evaluate hippocampus-dependent spatial memory in
rodents through an evaluation of the ability of rodents
to explore the new location of a familiar object with
respect to spatial cues [51]. Testing was conducted in an
open-field apparatus (50 × 50 × 40 cm). The mice were
first acclimated to the chamber for 10 minutes per day
for 2 days. On the third day during the acquisition
phase, mice were allowed to explore two identical ob-
jects, which were placed in the far corners of the arena
for 8 minutes. After a delay of 20 minutes, one object
was placed in the diagonally opposite corner. Thus, both
objects in the test phase were equally familiar, but one
was in a new location. The location of one of the two
objects was changed at random but counterbalanced for
each mouse. The objects were cleaned with 70% ethanol
after each trial. The time exploring each object was re-
corded. A discrimination index was calculated as [(new
location object exploring time)/(time spent exploring
both familiar and new location objects) × 100%] during
the test phase [52, 53].
Western blot analysis
Mouse brain tissue was homogenized in prechilled buf-
fer containing 50 mM Tris-HCl, (pH 7.4), 100 mM so-
dium fluoride, 1 mM sodium orthovanadate, 1 mM
ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraa-
cetic acid (EGTA), 0.5 mM 4-(2-aminoethyl)benzenesul-
fonyl fluoride hydrochloride (AEBSF), 10 μg/ml
aprotinin, 10 μg/ml leupeptin, and 4 μg/ml pepstatin.
Each homogenate was boiled in 2× Laemmli sample buf-
fer for 5 minutes, and protein concentration was mea-
sured by PierceTM 660-nm protein assay (Thermo
Scientific, Rockford, IL, USA). The samples were re-
solved by 10% SDS-PAGE and electrotransferred onto
Immobilon-P membranes (EMD Millipore, Billerica,
MA, USA). The blots were then probed with primary
antibodies (Table 1) and developed with the corres-
ponding HRP-conjugated secondary antibody and en-
hanced chemiluminescence kit (Pierce Biotechnology).
Densitometric quantification of protein bands in West-
ern blots was analyzed using Multi Gauge version 3.0
software (FUJIFILM North America, Valhalla, NY, USA).
Immunohistochemical staining
Immunohistochemical quantification of abnormally
hyperphosphorylated tau was performed on three or four
sections from three to five mice per group. Free-floating
sagittal sections were washed in 10 mM PBS (15 minutes,
three times each) and then incubated in 0.3% Triton X-
100 for 30 minutes. The sections were again washed in
10 mM PBS (15 minutes, three times each) and blocked
in blocking solution (5% normal goat serum, 0.1% Triton
X-100, and 0.05% Tween 20 in PBS) for 60 minutes. Sec-
tions were then incubated with AT8 (tau Ser202/
Thr205), paired helical filament 1 (PHF1; tau Ser396/
Ser404), R134d (total tau), 43D (tau 6–18), and 4G8
(amyloid precursor protein [APP]/Aβ) antibodies at 4 °C
overnight. After washing three times for 15 minutes each
with 10 mM PBS, sections were incubated with Alexa
Fluor 488-conjugated goat antimouse or antirabbit IgG
secondary antibodies (1:500; Molecular Probes, Eugene,
OR, USA) in 10 mM PBS with 0.05% Tween 20 for 2 h
at room temperature. Sections were subsequently
washed, mounted, and coverslipped using ProLong Gold
Antifade reagent with 4′,6-diamidino-2-phenylindole
(DAPI; Thermo Fisher Scientific). All images were ac-
quired using a Nikon Eclipse Ti microscope (Nikon In-
struments, Melville, NY, USA) and MetaMorph
microscopy automation and image analysis software (Mo-
lecular Devices, Sunnyvale, CA, USA), and ImageJ software
(National Institutes of Health, Bethesda, MD, USA) was
used to perform background subtraction and thresholding.
Thioflavin S staining
Briefly, free-floating sagittal sections were rinsed in PBS
for 10 minutes, then mounted onto glass slides and
allowed to air-dry overnight. Then thioflavin S staining
was performed as described before [28].
Human Aβ40 and Aβ42 measurements by ELISA
The tissue from forebrain was homogenized in 10
volumes of ice-cold guanidine hydrochloride buffer
(50 mM Tris-HCl, pH 8.0, 5.0 M guanidine HCl). The
homogenate was mixed for 4 h at room temperature and
then stored at −20 °C. For ELISA, each brain homogen-
ate was diluted 1:25 with ice-cold reaction buffer (5%
bovine serum albumin, 0.03% Tween 20, 2.1 mM AEBSF,
20 μg/ml aprotinin, 20 μg/ml leupeptin, 2.0 mM ethyl-
enediaminetetraacetic acid, pH 7.4) in modified Dulbec-
co’s PBS (8 mM sodium phosphate, 2 mM potassium
phosphate, 0.14 M NaCl, 10 mM KCl) and centrifuged
at 16,000 × g for 20 minutes at 4 °C. The final concentra-
tion of AEBSF was 1 mM to prevent proteolysis of Aβ
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peptides, and the final concentration of guanidine hydro-
chloride was 0.1 M. The supernatant was further diluted
1:1 (vol/vol) with standard diluent buffer and assessed
using an ELISA kit specific for human Aβ40 or Aβ42 and
calibrated with synthetic Aβ peptides (catalogue number
KHB3482; Invitrogen) according to the manufacturer’s
instructions. The Aβ40 and Aβ42 peptide standards were
prepared with the same composition of the buffer used
for the dilution of the samples.
Statistical analysis
Data were analyzed using Prism version 5.0 software
(GraphPad Software Inc., La Jolla, CA, USA) and one-
way or two-way analysis of variance (ANOVA) (as ap-
propriate) followed by a Bonferroni post hoc test.
Further intergroup comparisons were also performed
using unpaired, two-tailed t tests. All data are presented
as mean ± SEM. p < 0.05 was considered statistically
significant.
Results
Passive immunization with tau antibodies rescues
learning and memory deficits
To investigate whether passive immunization with tau
antibodies 43D and 77E9 can rescue cognitive impair-
ment in 3×Tg-AD mice, the Morris water maze task was
conducted 1 day after the sixth immunization (Fig. 1).
Passive immunization with 43D and 77E9 antibody nei-
ther caused any significant change in body weight
(Fig. 2a) nor produced any neurological deficits during
the entire period of this study. 3×Tg-AD mice immu-
nized with 43D antibody took significantly less time than
the mice treated with mouse IgG to find the hidden plat-
form in the acquisition phase (Fig. 2b). More import-
antly, in the probe trial, 3×Tg-AD mice treated with 43D
antibody spent longer in the target quadrant (Fig. 2c),
had more target crossings (Fig. 2d), and took much less
time to enter the target quadrant (Fig. 2e) than IgG-
treated animals.
Unlike the mice immunized with 43D, the 77E9
antibody-immunized animals took amounts of time to
reach the hidden platform in acquisition phase similar to
those of the mouse IgG-treated controls (Fig. 2b). How-
ever, the mice treated with 77E9 showed similar per-
formance as the 3×Tg-AD mice treated with 43D
antibody in the probe trial (Fig. 2c–e). Animals immu-
nized with a 1:1 mixture of 43D and 77E9 showed per-
formance in the probe test similar to those treated with
43D alone. No significant difference was observed in
swim speed during probe trials among all groups of ani-
mals (Fig. 2f ). These results indicated that passive
immunization targeting N-terminal tau, especially with
43D, could reverse spatial memory impairment without
causing any side effects in 3×Tg-AD mice.
To examine whether immunization with tau antibodies
could rescue the short-term memory impairment in
3×Tg-AD mice, we conducted a one-trial novel object
recognition task with a 20-minute interval between the
sample phase and the test phase. In the one-trial novel
object recognition test, two identical objects, object 1 on
location 1 and object 2 on location 2, were placed. For
some unknown reason, the mice spent unequal amounts
of time exploring the two identical objects during the 8-
minute sample phase (Fig. 2g), which did not correlate
with any of the two objects. Therefore, the less-explored
object during sample phase was changed to a novel ob-
ject during a 5-minute test phase. 3×Tg-AD mice spent
less time exploring the novel object than the familiar ob-
ject in the test phase than the WT mice did (Fig. 2h),
whereas 3×Tg-AD mice immunized with 43D and 77E9
spent longer times exploring the novel object than did
the 3×Tg-AD mice treated with mouse IgG, and
amounts of time similar to WT mice (Fig. 2h). These re-
sults clearly indicate short-term memory impairment in
3×Tg-AD mice and its rescue by immunization with six
doses of 43D and 77E9 antibodies.
The beneficial effect of immunization with tau antibodies
on cognition is sustained even after discontinuing
immunization
To assess whether the beneficial effect of immunizations
with 43D and 77E9 antibodies could last beyond the
immunization period, the novel object location task was
employed to measure the short-term memory at 100
days after the last immunization. All mice spent similar
amounts of time exploring the objects at location 1 and
location 2 in the sample phase (Fig. 3a). 3×Tg-AD mice
immunized with 43D antibody spent much more time
exploring the object in a new location than the mice
treated with mouse IgG in the test phase (Fig. 3b).
3×Tg-AD mice immunized with 77E9 antibody also
showed a clear trend (unpaired t test, 3×Tg-IgG vs.
3×Tg-77E9, p = 0.07) toward spending more time explor-
ing the object at a novel location than did the mouse
IgG-treated control mice (Fig. 3b). These results indicate
that the beneficial effect of immunization with 43D and
77E9 antibodies on short-term memory can last at least
approximately 3 months after discontinuing immunization.
Two doses of immunization with 43D and 77E9
antibodies decreases total tau in the hippocampus
To investigate whether immunization with tau anti-
bodies can reduce tau pathology in a dose-dependent
manner, we first immunized the 12-month-old female
3×Tg-AD mice with mouse IgG, 43D, and 77E9 once per
week for 2 weeks (15 μg/mouse intravenously), and then
killed the mice 1 day after their second immunization.
Both 43D and 77E9 reduced human transgenic tau
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(43D) and total tau level (tested with R134d and 92e
antibodies) in the hippocampus (Fig. 4a). However, we
did not observe a significant decrease of hyperpho-
sphorylated tau after two doses of immunization with
43D or 77E9 antibodies (Fig. 4a). These results indi-
cate that short-term immunization with normal N-
terminal tau 43D and 77E9 antibodies can reduce
total tau but not hyperphosphorylated tau levels in
mouse brain.
Six doses of immunization with 43D reduces both total
and hyperphosphorylated tau in hippocampus
To determine the effect of long-term immunization, we
immunized 15-month-old 3×Tg-AD mice with mouse
Fig. 2 (See legend on next page.)
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IgG and 43D once weekly for 6 weeks (15 μg/mouse
intravenously), and we killed the mice 1 day after their
last immunization. Similarly to two doses, six doses of
immunization decreased both human transgenic tau
assayed with antibody 43D and total tau level deter-
mined with antibodies R134d and 92e in hippocampus
(Fig. 4b). Importantly, six doses also significantly re-
duced hyperphosphorylated tau at Ser262/Ser356 (12E8)
and Ser396/Ser404 (PHF1) sites, and it also showed a
clear trend toward reducing tau hyperphosphorylation at
Thr205 in hippocampus (Fig. 4b–e). These results indi-
cate that long-term immunization with normal N-
terminal tau antibody 43D could decrease tau pathology
in mouse brain.
Immunization with 43D but not 77E9 decreases APP and
Aβ accumulation in moderate to severe stages of plaque
pathology
3×Tg-AD mice develop amyloid plaques starting around
9 months of age. They are first apparent in the cortex
and progress to the hippocampus with age [42–44]. In
the present study, we determined whether immunization
with tau antibodies could alter the level of APP and Aβ
plaques. Immunization with 43D but not 77E9 antibody
decreased APP levels in forebrain (Fig. 5a) and showed a
trend of reduced APP staining in CA1 (Fig. 5b).
Immunization with 43D also showed a reduction in thio-
flavin S-positive Aβ plaque load in subiculum (Fig. 5c)
and showed a trend toward reduction in the levels of
Fig. 3 Immunization with tau antibodies 43D and 77E9 improves spatial memory beyond the period of immunization in 3×Tg-AD mice. Novel
object location test was carried out 100 days after the last injection (see Fig. 1). a The percentage of time spent exploring two identical objects
during sample phase (two-way ANOVA, F = 0.21, dfd = 56, p = 0.6484). b Discrimination index (time exploring object at novel location/time
exploring object novel and familiar locations) × 100% in test phase (one-way ANOVA, F = 2.836, p = 0.0357; Bonferroni multiple comparisons test,
WT-IgG vs. 3×Tg-IgG, p < 0.05; 3×Tg-IgG vs. 3×Tg-43D, p < 0.05). n = 6 and n = 5 for WT mice treated with IgG or 43D + 77E9, respectively; n = 6 for
3×Tg-AD mice treated with 43D, 77E9, or 43D + 77E9; and n = 8 for 3×Tg-AD mice treated with IgG. Data are reported as mean ± SEM. *p < 0.05
by one-way ANOVA followed by a Bonferroni post hoc test. ANOVA Analysis of variance, IgG Immunoglobulin G, 3×Tg
Triple-transgenic, WT Wild type
(See figure on previous page.)
Fig. 2 Immunization with tau antibodies 43D and 77E9 rescues cognitive impairment without any side effects in 3×Tg-AD mice. a The
body weights of the mice were measured once per week. b–f The Morris water maze test was carried out after the sixth immunization
(see Fig. 1). b The escape latency (in seconds) to reach the hidden platform during acquisition phase for 5 days (two-way ANOVA, WT-
IgG vs. 3×Tg-IgG, F = 8.47, dfd = 90, p < 0.01; 3×Tg-IgG vs. 3×Tg-43D, F = 12.95, dfd = 75, p < 0.001; 3×Tg-IgG vs. 3×Tg-77E9, F = 0.23, dfd =
70, p = 0.63). c Percentage of time in the quadrant during the probe trial (two-way ANOVA, F = 241.59, dfd = 200, p < 0.0001; Bonferroni
posttests for target quadrant, WT-IgG vs. 3×Tg-IgG, p < 0.01; 3×Tg-IgG vs. 3×Tg-43D, p < 0.001; 3×Tg-IgG vs. 3×Tg-77E9, p < 0.01). d Number
of target crossings in the probe trial (one-way ANOVA, F = 3.666, p = 0.0067; Bonferroni multiple comparisons test, WT-IgG vs. 3×Tg-IgG, p
< 0.05; 3×Tg-IgG vs. 3×Tg-43D, p < 0.01; 3×Tg-IgG vs. 3×Tg-77E9, p < 0.01). e Latency to first entrance into target zone (one-way ANOVA, F
= 2.717, p = 0.0301; Bonferroni multiple comparisons test, WT-IgG vs. 3×Tg-IgG, p < 0.05; 3×Tg-IgG vs. 3×Tg-43D, p < 0.05). f The average
swim speed during the probe trial (one-way ANOVA, F = 1.003, p = 0.4257). g and h, One-trial novel object recognition test (see Fig. 1). g
The percentage of time spent exploring two identical objects during sample phase (two-way ANOVA, F = 18.93, dfd = 122, p < 0.0001). h
Discrimination index (time spent exploring novel object/time spent exploring novel and familiar objects) × 100% in test phase (one-way
ANOVA, F = 4.517, p = 0.0014; Bonferroni multiple comparisons test, WT-IgG vs. 3×Tg-IgG, p < 0.01; 3×Tg-IgG vs. 3×Tg-43D, p < 0.001; 3×Tg-
IgG vs. 3×Tg-77E9, p < 0.01). n = 12 for WT mice treated with IgG or 43D + 77E9, 3×Tg-AD mice treated with 43D, 77E9, or 43D + 77E9;
and n = 14 for 3×Tg-AD mice treated with IgG. Data are reported as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 by ANOVA followed by
a Bonferroni post hoc test. AD Alzheimer’s disease, ANOVA Analysis of variance, IgG Immunoglobulin G, 3×Tg Triple-transgenic, WT
Wild type
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Aβ40 and Aβ42 (unpaired t test, 3×Tg-IgG vs. 3×Tg-43D,
p = 0.08) in forebrain (Fig. 5d–f ) at 6 days after the last
dose. However, the levels of Aβ40 and Aβ42, as well as
the ratio of Aβ42/Aβ40, were similar among 43D, 77E9,
and mouse IgG-immunized 3×Tg-AD mice at 16 weeks
after the last dose (data not shown).
Consistently, immunization with 43D decreased APP
levels and Aβ plaque loads 1 day after the sixth
immunization (Fig. 5g–i). Importantly, there was no
cross-reaction between 43D and Aβ or Aβ plaques
(Fig. 5j and k). These data suggest that immunotherapy
targeting tau 6–18 but not tau 184–195 could reduce
the amyloid plaque load, which can persist long after the
discontinuation of the treatment.
Immunization with 43D leads to activation of microglia and
increased levels of complement components C1q and C9
To explore the possible mechanisms involved by which
immunization with 43D ameliorates Aβ pathology, first
we investigated the involvement of microglia. Although
the microglial level tested by Western blots with Iba1
antibody did not show a significant difference between
43D- and IgG-treated mice in the hippocampus (Fig. 6b),
the 43D-immunized mice showed much more activated
microglia with larger somata and short, thick extensions
than the mice treated with mouse IgG in the subiculum
region (Fig. 6a). Importantly, activated microglia were
found to be aggregated around thioflavin S-positive
plaques in phagocytizing positions (Fig. 6a). These data
suggest that 43D immunization with 43D draws micro-
glia to Aβ plaques. Additionally, immunization with 43D
also increased C1q and C9 levels (Fig. 6c), which sug-
gests that this treatment could possibly induce the
activation of complement system and consequently the
clearance of Aβ plaques by microglia in 3×Tg-AD mice.
Tau hyperphosphorylation is reduced beyond the period
of immunization with 43D and 77E9
To assess whether immunization with antibodies 43D
and 77E9 reduces tau hyperphosphorylation beyond
the period of the treatment, we investigated the levels
of total and hyperphosphorylated taus by Western blot
analysis in the forebrain 1 and 16 weeks after the last
immunization. We found an increase of total tau but a
Fig. 4 Immunization with 43D dose-dependently decreases tau pathology. Immunization with (a) two doses of 43D and 77E9 antibody or (b–e)
six doses of 43D. Mice were killed 1 day after their last injection. a and b Representative Western blots of hippocampus developed with R134d
and 92e against total tau, 43D against human transgenic tau, and several phosphorylation-dependent and site-specific tau antibodies.
Densitometric quantification of blots after normalization with GAPDH is shown. Five of the 3×Tg-AD mice per group in (a) and three or
five of the 3×Tg-AD mice for IgG or 43D treatment, respectively, are shown. Data are percentages of mouse IgG (100%)-treated animals
reported as mean ± SEM. Immunostaining of CA1 from 3×Tg-AD mice immunized with six doses of 43D or control IgG with (c) R134d, (d)
43D, or (e) PHF1 antibodies. The quantification of R134d, 43D, and PHF1 immunostaining intensity in total CA1 region was based on two
sections from each of three or five mice per group. Data are shown as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 by ANOVA followed
by a Bonferroni post hoc test for two doses of immunization or by unpaired two-tailed t test for six doses of immunization. AD Alzheimer’s disease,
ANOVA Analysis of variance, GAPDH Glyceraldehyde 3-phosphate dehydrogenase, IgG Immunoglobulin G, 3×Tg Triple-transgenic
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decrease in tau hyperphosphorylation (p-tau normal-
ized with total tau) at Thr231 and 12E8 (Ser262/
Ser356) sites, as well as a trend at PHF1 (Ser396/
Ser404, p = 0.098) sites in the forebrain of 43D-
immunized 3×Tg-AD mice (Fig. 7a and b). Similar re-
sults were found in the forebrain at 16 weeks after the
last injection (data not shown). These findings
suggested that the beneficial effect of immunization
with 43D could last beyond the period of the
treatment.
Additionally, we did not observe any change of an
apoptotic marker, cleaved caspase-3, and a neuronal
marker, NeuN, in forebrain (Fig. 7c and d). These data
indicate that treatments with IgG and tau antibodies
Fig. 5 Immunization with 43D but not 77E9 decreases Aβ pathology in 3×Tg-AD mice. a–f Analysis of Aβ pathology 1 week after seventh dose
(see Fig. 1). a Representative Western blots of forebrain developed with APP. Densitometric quantification of blots after normalization with
GAPDH. Immunostaining of (b) CA1 with 4G8 and (c) subiculum with thioflavin S in 3×Tg-AD mice. Quantification of APP staining with 4G8 in
CA1 and amyloid plaques in subiculum stained with thioflavin S from two sections per mouse of five or six mice per group. The levels of total (d)
Aβ40 and (e) Aβ42 (unpaired t test, 3×Tg-IgG vs. 3×Tg-43D, p = 0.08) and (f) the ratio of Aβ42/Aβ40 in forebrain was quantified by ELISA. g–i Aβ
pathology in 3×Tg-AD mice 1 day after the sixth injection. 4G8 staining in (g) CA1 and (h) subiculum and (i) thioflavin S staining in subiculum in
3×Tg-AD mice. 43D did not cross-react with Aβ (j) and Aβ plaques (k). j Thirty micrograms of 3×Tg-AD mouse brain homogenate (lanes 1–3) and
0.4 μg of purified Aβ (lane 4) were loaded. Nitrocellulose membrane was first developed with 43D antibody (left panel) and then developed with
4G8 antibody (right panel). k Double-stained 3×Tg-AD mouse brain sections with 43D antibody and thioflavin S. Top row: CA1 and subiculum area
(original magnification × 10). Bottom row: Subiculum area (original magnification × 20). Quantification of APP staining in CA1 and amyloid plaques
in subiculum stained with 4G8 and thioflavin S from two sections per mouse of three or five animals per group. Data are shown as mean ± SEM.
*p < 0.05, **p < 0.01, ***p < 0.001 by ANOVA followed by a Bonferroni post hoc test for two doses of immunization or by unpaired two-tailed t test
for six doses of immunization. AD Alzheimer’s disease, ANOVA Analysis of variance, APP Amyloid precursor protein, Aβ Amyloid-β, ELISA
Enzyme-linked immunosorbent assay, GAPDH Glyceraldehyde 3-phosphate dehydrogenase, IgG Immunoglobulin G, MW Molecular weight,
3×Tg Triple-transgenic, TS Thioflavin S, WT Wild type
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43D and 77E9 did not cause neuronal apoptosis or
change the neuronal numbers.
Discussion
A central objective of dementia field is to inhibit, or at
least effectively modify, the course of AD. In the present
study, we examined the dose-dependent effect of treat-
ment with tau antibodies on pathology and cognitive
performance and how long the beneficial effect could be
sustained after discontinuing immunization. We found
that two doses of immunization with tau antibodies
(15 μg/mouse, intravenously, once per week) could de-
crease the total tau level, but not the level of hyperpho-
sphorylated tau, in 3×Tg-AD mice. Six doses of
immunization, however, reduced both total tau and
hyperphosphorylated tau levels in hippocampus and res-
cued both spatial reference and episodic memory impair-
ments in 3×Tg-AD mice. Importantly, the beneficial
effect on short-term reference memory was sustained at
least 3 months after discontinuation of immunization, as
determined by a novel object location test. Moreover,
immunization with 43D antibody induced activation of
microglia and the complement system, which could have
facilitated the clearance of Aβ plaques in 3×Tg-AD mice.
3×Tg-AD mice develop Aβ accumulation at approxi-
mately 9 months of age and tau pathology starting at 12
months of age [42–44]. Immunization of 12-month-old
female 3×Tg-AD mice with 43D and 77E9 antibodies
once weekly for 6 weeks rescued cognitive impairment,
and the beneficial effect on cognitive improvement
lasted at least 3 months after discontinuation of the
treatment with tau antibodies. However, we observed a
small change in tau pathology by Western blot analysis
after behavioral tests that showed a marked improve-
ment in cognitive performance. These findings suggest
that the beneficial effect on behavioral improvement
may last much longer than the effect on tau pathology,
as well as that a certain threshold of the pathology is
probably required to affect cognitive performance. The
bulk of the tau pathology develops from about 12–18
months of age in 3×Tg-AD mice, and it is possible that
the rate of tau pathology formation was more than its
clearance after the discontinuance of the immunization.
Therefore, to investigate whether tau immunization has
a dose-dependent beneficial effect on tau pathology, we
immunized the 3×Tg-AD mice employing two doses and
six doses once per week (15 μg/mouse intravenously)
and killed the mice 1 day later. We found that two doses
of immunization decreased total tau but not hyperpho-
sphorylated tau, whereas six doses of tau antibodies re-
duced both total tau and hyperphosphorylated tau.
These data indicate that immunization with tau anti-
bodies dose-dependently ameliorates the pathology in
3×Tg-AD mice and that extracellular tau, which is
mostly nonhyperphosphorylated, is the primary target of
the tau antibodies.
Tau pathology is well documented to propagate in a
predictable pattern [37, 38]. Tau immunotherapy can
target its transcellular propagation and clear pathological
tau. Recently, several studies indicated that tau
Fig. 6 Immunization with 43D increases the activity of microglia and the complement system in 3×Tg-AD mice. The activation of microglia and
the complement system was assessed 1 day after the sixth injection. a Thioflavin S staining and Iba1 immunofluorescence were performed in the
subiculum area. White arrows highlight activated microglial cells aggregated around Aβ plaques. Representative Western blots of hippocampus
developed (b) with Iba1 antibody and (c) with complement components C1q and C9 antibodies and densitometric quantification of blots after
normalization with GAPDH. Three or five representative 3×Tg-AD mice in the IgG or 43D treatment group, respectively, are shown. Data are
percentages of mouse IgG (100%)-treated animals, reported as mean ± SEM. *p < 0.05 by unpaired two-tailed Student’s t test. AD Alzheimer’s
disease, Aβ Amyloid-β, GAPDH Glyceraldehyde 3-phosphate dehydrogenase, IgG Immunoglobulin G, 3×Tg Triple-transgenic
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antibodies can be taken up by neurons and promote
intracellular sequestration and clearance of tau [16, 20,
25, 54–57]. Fc receptor-mediated endocytosis and the
endosome-autophagosome-lysosome system are believed
to play a critical role in antibody-mediated clearance of
tau pathology. In a neuron, antibodies localize in the
endosomal-autophagosome-lysosome system and pro-
mote tau clearance by disassembling tau aggregates. Im-
portantly, antibody uptake into neurons has been shown
to be a prerequisite for acute tau clearance. This intra-
cellular interaction may sequester the tau protein, pre-
venting its release into the extracellular space and
subsequent spread in the brain [58]. In the present
study, 43D was found to recognize human tau in neur-
onal somata and dendrites (Fig. 4d) and 77E9 mostly la-
beled tau in axons (data not shown). Whether both
mechanisms are involved in the beneficial effects of 43D
and 77E9 immunization is not currently understood.
Fig. 7 Effect of immunization with 43D and 77E9 antibodies on tau pathology lasts several weeks after the last treatment. a Representative
Western blots of forebrain developed with R134d against total tau and with several phosphorylation-dependent and site-specific tau antibodies.
b Densitometric quantification of phosphorylated tau after normalization with total tau (R134d). c Western blots of forebrain developed with
antibodies to apoptotic marker cleaved caspase-3 and neuronal marker NeuN. d Quantification of cleaved caspase-3 and NeuN from (c). n = 5 for
WT mice treated with IgG, 43D, and 77E9, and 3×Tg-AD mice treated with 43D + 77E9; n = 6 for 3×Tg-AD mice treated with IgG, 43D, and 77E9.
Data are percentages of mouse IgG (100%)-treated animals, reported as mean ± SEM. *p < 0.05, **p < 0.01 by one-way ANOVA followed by
Bonferroni post hoc test. AD Alzheimer’s disease, ANOVA Analysis of variance, Aβ Amyloid-β, GAPDH Glyceraldehyde 3-phosphate dehydrogenase,
IgG Immunoglobulin G, pS199 Phospho-tau (Ser199), pT205 Phospho-tau (Thr205), 3×Tg Triple-transgenic, WT Wild type
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Tau is primarily a cytoplasmic protein that stabilizes
microtubules. Recent studies have shown that tau can be
released into the extracellular space from neurons as a
physiological process that is independent from neuronal
death [59, 60]. Additionally, an increase in the level of
tau in cerebrospinal fluid (CSF) is associated with AD
and is linked to Aβ deposition [61, 62]. Extracellular tau
seeds can enter neurons and further induce intracellular
tau accumulation and subsequent spreading of tau
pathology. Importantly, mostly N-terminal but not C-
terminal fragments are found in extracellular tau in AD
CSF [63, 64]. In the present study, we found that two
doses of immunization decreased only total tau, but that
six doses removed both total and hyperphosphorylated
tau. Two doses of immunization with 43D against N-
terminal tau 6–18 probably first clears the extracellular
tau, which is largely nonhyperphosphorylated [65]. How-
ever, a total of six doses of immunization with 43D and
77E9 antibodies probably removes both extracellular and
intracellular tau.
Notably, we found that immunization with 43D de-
creased Aβ pathology, though 43D did not cross-react
with Aβ and Aβ plaques. Our findings are consistent
with studies that showed that tau pathology precedes Aβ
pathology in aged and AD brains [66, 67]. One possible
mechanism is that 43D treatment rescues neurofibrillary
degeneration and decreases Aβ production via reduction
of APP synthesis and/or its amyloidogenic processing,
because immunization with 43D decreased both APP
and Aβ levels in the forebrain. Clearance of extracellular
tau with tau antibodies probably inhibits Aβ production
through inhibition of neurofibrillary degeneration [63].
Therefore, immunotherapy targeting N-terminal tau not
only directly decreases tau pathology but also amelio-
rates Aβ pathology, which may form a positive feed-
forward regulation in vivo. The exact nature of the
molecular mechanism involved in the reduction of APP
and Aβ production by tau immunization is not currently
understood. We speculate that the reduction in amyloi-
dogenic processing of APP in tau-immunized mice could
be secondary to improvement in neuronal connectivity
as a result of decreased neurofibrillary degeneration.
One prominent feature of AD neuropathology is the
association of activated proteins of the classical comple-
ment pathway with the lesions. The full range of clas-
sical pathway complement proteins from C1q to C5b-9
(membrane attack complex) has been demonstrated by
immunocytochemical staining to be associated with
senile plaques, NFTs, neuropil threads, and dystrophic
neurites in AD brain [68, 69]. Binding of C1q and C3 to
amyloid plaques can activate the classical and alternative
pathways of the complement system. The complement
system may be useful in eliminating aggregated and
toxic proteins associated with these lesions and thus
may have a protective effect [70]. C3 plays a detrimental
role in complement full activation. Knockout of C3 or
overexpression of C3 convertase inhibitor (Crry) was
reported to increase the amyloid load burden but to
reduce phagocytic microglia [71, 72]. Microglia are the
phagocytes of the brain and express complement recep-
tor CR3. C3 promotes plaque clearance via triggering of
Aβ phagocytosis by microglia [73, 74]. Although in the
present study the C3 level was undetectable by Western
blotting in brains of 3×Tg-AD mice, immunization with
43D increased the levels of C1q, the first protein in the
complement cascade, and C9, the late-stage activation
marker, and it promoted microglial activation and aggre-
gation around Aβ plaques. We did not observe an asso-
ciation between C1q and Aβ plaques by
immunohistochemistry in 3×Tg-AD mice, which is con-
sistent with a previous report [75]. Currently, the exact
mechanism is not known. We suspect that inhibition of
Aβ pathology occurs by passive immunization with 43D,
probably on one hand owing to improvement of neur-
onal connectivity leading to a decrease in amyloidogenic
processing of APP and on the other hand owing to
enhancement of the clearance of amyloid plaque load by
activation of the complement and phagocytosis by the
microglia.
Recently, tau immunotherapy has shown promising
beneficial effects in animal models, and several clinical
trials on tau immunotherapy are underway or are at
various discovery stages [58]. The key question in tau
immunotherapy is which site/domain to target. D’Ab-
ramo et al. demonstrated that MC1 (tau 312–322)
targeting PHF-tau was more efficacious than the high-
affinity DA31 (tau 150–190) antibody against normal
tau, which suggests that antibody specificity is more im-
portant than its affinity in therapeutic applications [76].
Tau antibodies HJ8.5 (tau 25–30), HJ 9.4 (tau 7–13), and
HJ9.3 (tau 306–320) were developed by blocking tau
seeding in vitro, but only HJ8.5 and HJ9.4, and not
HJ9.3, rescued contextual fear deficits, though HJ8.5 and
HJ9.3 strongly decreased pathological tau seeds in vivo
[23]. In the present study, 43D and 77E9 targeted tau 6–
18 and tau 184–195, respectively, and the isotype of
both antibodies is IgG1 kappa light chain. Thus, the dif-
ferent domains of tau-targeted epitope by 43D and 77E9
may represent one possible explanation for better effects
with 43D than with 77E9 in reducing tau pathology,
rescuing cognitive deficits, and ameliorating the Aβ
pathology. These data imply that the sites/domains tar-
geted by tau antibodies may play a pivotal role in the
beneficial therapeutic outcome.
Conclusions
The present study shows that passive immunization tar-
geting N-terminal tau 6–18 and 184–195 with 43D and
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77E9 antibodies can reduce total and hyperphosphory-
lated tau levels dose-dependently and can rescue spatial
and short-term episodic memory impairments. Import-
antly, the beneficial effect of immunization with 43D
and 77E9 on tau hyperphosphorylation and short-term
memory improvement is sustained at least 3 months
after discontinuation of the immunization. The passive
immunization with tau antibody 43D can also decrease
APP, amyloid plaque load, and Aβ level. Overall, this
study shows that passive immunization targeting the N-
terminal projection domain of tau offers a potential
promising treatment opportunity for AD and probably
other tauopathies.
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